Mr. Steinkrauss is the founder of OWL CFO Consulting, a consulting firm providing part-time CFO services to companies in the biotechnology industry. He previously served as CFO and chief administrative officer of Curis, a publicly traded biotechnology company.
In his new role, Mr. Steinkrauss will lead financial strategy and operations as OcuTerra advances its lead asset for the treatment of diabetic retinopathy, OTT166.
